Amgen, Pfizer Settle Patent Suit on Biosimilar of Neupogen Drug

Amgen had claimed that a biosimilar version of Neupogen by Pfizer’s Hospira unit infringed a patent for the cancer drug.

• No details provided in stipulation and proposed order of dismissal, filed Wednesday but not yet approved in federal court in Wilmington, Delaware
• Neupogen, a white blood cell booster, has been on the market since 1991
• Biosimilars are nearly identical versions of branded biological drugs and are made from living organisms
• Neupogen had U.S. sales of $54 million during the first six months of 2021, 26% less than during the same period in 2020, Amgen said Aug. 4 in its ...